| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6191591 | European Journal of Surgical Oncology (EJSO) | 2015 | 6 Pages |
Abstract
The proportion of patients diagnosed with synchronous PC from CRC treated with CRS-HIPEC has increased significantly over time and currently almost 10% of PC patients are treated with CRS-HIPEC. Median survival in this population based group is 32.3 months.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L.G.E.M. Razenberg, Y.R.B.M. van Gestel, G.-J. Creemers, V.J. Verwaal, V.E.P.P. Lemmens, I.H.J.T. de Hingh,